Loading...
Loading...
- Merck & Co Inc's MRK Q2 sales reached $14.60 billion, +28% Y/Y, beating the consensus of $13.87 billion. Excluding the foreign exchange impact and COVID-19 treatment sales, revenues were up 20%.
- Pharmaceutical sales increased 28% to $12.75 billion. The sales increased 16%, excluding Lagevrio (molnupiravir), primarily driven by oncology, vaccines, and hospital acute care products.
- COVID-19 treatment drug Lagevrio (molnupiravir) sales were $1.2 billion, lower than the $3.2 billion generated in Q1 FY22.
- Growth in oncology was primarily driven by higher sales of Keytruda, which rose 26% to $5.3 billion.
- Vaccine sales rebounded, and Gardasil/ Gardasil 9 sales were up 36% to $1.7 billion, primarily driven by strong global demand, particularly in China.
- Adjusted EPS of $1.87 also surpassed the analysts' estimate of $1.69 and was up from $0.61 a year ago.
- 2022 Guidance: Merck expects FY22 sales of $57.5 billion - $58.5 billion compared to prior guidance of $56.9 billion - $58.1 billion and the consensus of $58.1 billion.
- The company reaffirms sales of $5 billion - $5.5 billion from Lagevrio.
- It expects an adjusted EPS of $7.25 - $7.35 (consensus $7.36) versus the previous range of $7.24 - $7.36.
- Price Action: MRK shares are down 1.09% at $90.24 during the premarket session on the last check Thursday.
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in